Genomic Vision
GV | XPAR
Overview
Corporate Details
- ISIN(s):
- FR0011799907
- LEI:
- 969500UXJNBY1C8Y8471
- Country:
- France
- Address:
- 80 RUE DES MEUNIERS, 92220 BAGNEUX
- Website:
- http://www.genomicvision.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
GENOMIC VISION develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. GENOMIC VISION uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GENOMIC VISION initial focus is towards early cancer detection and drug therapy monitoring. The company possesses an unrivalled capability for discovering genomic biomarkers implicated in the predisposition and development of many forms of cancer and in following and analyzing DNA replication during cell division. This provides a unique approach for evaluating the efficacy of new drugs on the cell cycle.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2023-11-17 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 171.1 KB | |
2023-11-17 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 168.7 KB | |
2023-11-14 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 183.9 KB | |
2023-11-14 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 182.8 KB | |
2023-11-08 18:38 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 79.6 KB | |
2023-11-07 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 165.9 KB | |
2023-11-03 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 133.1 KB | |
2023-11-03 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 134.9 KB | |
2023-11-02 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 166.5 KB | |
2023-11-02 07:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 165.6 KB | |
2023-10-24 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 123.8 KB | |
2023-10-24 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 122.3 KB | |
2023-10-19 09:29 |
Major Shareholding Notification
Franchissement de seuils
|
French | 272.4 KB | |
2023-10-18 14:49 |
Regulatory News Service
Franchissement de seuils
|
French | 272.6 KB | |
2023-10-12 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 157.0 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |